enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. New treatment may stop and potentially reverse some nerve ...

   www.aol.com/treatment-may-stop-potentially...

   Multiple sclerosis (MS) is an autoimmune disorder in which the immune system attacks and destroys the myelin sheath of nerve cells. It most commonly strikes people between the ages of 20 and 40.

3. Peginterferon beta-1a - Wikipedia

   en.wikipedia.org/wiki/Peginterferon_Beta-1a

   Peginterferon beta-1a, sold under the brand name Plegridy, is medication used to treat multiple sclerosis. [4] [5]The most common side effects include headache, muscle pain, joint pain, influenza (flu)-like symptoms, pyrexia (fever), chills, asthenia (weakness), and erythema (reddening of the skin), pain or pruritus (itching) at the injection site.

4. Management of multiple sclerosis - Wikipedia

   en.wikipedia.org/wiki/Management_of_multiple...

   In March 2017, ocrelizumab was approved in the United States for the treatment of primary progressive multiple sclerosis in adults. [22] [42] It is also used for the treatment of relapsing forms of multiple sclerosis, to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. [42]

5. Interferon beta-1a - Wikipedia

   en.wikipedia.org/wiki/Interferon_beta-1a

   As of 2020, the National Average Drug Acquisition Cost (NADAC) in the United States for Avonex was $6,872.94 for a 30 mcg kit. [32] Avonex and Rebif are on the top ten best-selling multiple sclerosis drugs of 2013. [33] It is an example of a specialty drug that would only be available through a specialty pharmacy. This is because it requires a ...

6. Ofatumumab - Wikipedia

   en.wikipedia.org/wiki/Ofatumumab

   Ofatumumab (Kesimpta 20 mg solution for injection in pre-filled syringe/pen) is indicated for the treatment of relapsing forms of multiple sclerosis in adults. [9] [11] [16] The recommended dose is 20 mg of ofatumumab administered by subcutaneous injection with monthly dosing following loading.

7. UPDATE 1-U.S. group says Novartis MS drug price out of line ...

   www.aol.com/news/1-u-group-says-novartis...

   A U.S. group that reviews the value of medicines issued a critical report on Novartis's new multiple sclerosis drug Mayzent, calling its $88,561 list price "far out of line" compared with its ...